How to Tell When A Drug Company Fibs About Clinical Trial Results
By Adam Feuerstein,
The Street
| 07. 03. 2012
Osiris Therapeutics
"disappeared" important data when the company announced results Monday
from a mid-stage study of its stem cell therapy Prochymal in heart
attack patients.
Naturally, Osiris didn't come out and tell investors that it was
issuing a misleading press release on the Prochymal heart attack study.
Instead, the company claimed the study was a success. That's not true.
Figuring out Osiris' deception wasn't that difficult if you know how to
parse the language of clinical trial results and look at independent
sources of information for the truth.
Ride along with me as I pick apart Osiris' statements regarding the Prochymal heart attack study.
Interpreting clinical trial results with a skeptical eye is a crucial
tool for all biotech investors, so apply these skills universally
whenever a drug or biotech company tries to convince you that its drug
works. Hopefully, you'll find most companies are telling the truth, but
sadly and too often, bullish pronouncements about boffo clinical trial
data are just spin jobs ginned up to plaster over problems and bad data.
Here's what Osiris issued Monday:
Osiris...
Related Articles
By Megan Agnew, The Times | 09.15.2024
Faith Hartley always wanted two girls — a blonde and a redhead. “I thought, I’ll have one that looks like me,” says Hartley, 35, smoothing her golden hair in the Los Angeles valley home she shares with her husband, Neil...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...
By Smriti Mallapaty, Nature | 09.11.2024
Under his microscope, Jun Wu could see several tiny spheres, each less than 1 millimetre wide. They looked just like human embryos: a dark cluster of cells surrounded by a cavity, and then another ring of cells.
But Wu, a...